1. Home
  2. XOMAP vs NAMSW Comparison

XOMAP vs NAMSW Comparison

Compare XOMAP & NAMSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOMAP
  • NAMSW
  • Stock Information
  • Founded
  • XOMAP N/A
  • NAMSW N/A
  • Country
  • XOMAP United States
  • NAMSW Netherlands
  • Employees
  • XOMAP 13
  • NAMSW 29
  • Industry
  • XOMAP Biotechnology: Pharmaceutical Preparations
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • Sector
  • XOMAP Health Care
  • NAMSW Health Care
  • Exchange
  • XOMAP Nasdaq
  • NAMSW Nasdaq
  • Market Cap
  • XOMAP N/A
  • NAMSW N/A
  • IPO Year
  • XOMAP N/A
  • NAMSW N/A
  • Fundamental
  • Price
  • XOMAP $25.42
  • NAMSW $9.00
  • Analyst Decision
  • XOMAP
  • NAMSW
  • Analyst Count
  • XOMAP 0
  • NAMSW 0
  • Target Price
  • XOMAP N/A
  • NAMSW N/A
  • AVG Volume (30 Days)
  • XOMAP N/A
  • NAMSW N/A
  • Earning Date
  • XOMAP N/A
  • NAMSW N/A
  • Dividend Yield
  • XOMAP N/A
  • NAMSW N/A
  • EPS Growth
  • XOMAP N/A
  • NAMSW N/A
  • EPS
  • XOMAP N/A
  • NAMSW N/A
  • Revenue
  • XOMAP N/A
  • NAMSW N/A
  • Revenue This Year
  • XOMAP N/A
  • NAMSW N/A
  • Revenue Next Year
  • XOMAP N/A
  • NAMSW N/A
  • P/E Ratio
  • XOMAP N/A
  • NAMSW N/A
  • Revenue Growth
  • XOMAP N/A
  • NAMSW N/A
  • 52 Week Low
  • XOMAP N/A
  • NAMSW N/A
  • 52 Week High
  • XOMAP N/A
  • NAMSW N/A
  • Technical
  • Relative Strength Index (RSI)
  • XOMAP 47.85
  • NAMSW 47.49
  • Support Level
  • XOMAP $25.32
  • NAMSW $9.40
  • Resistance Level
  • XOMAP $25.90
  • NAMSW $10.14
  • Average True Range (ATR)
  • XOMAP 0.37
  • NAMSW 0.44
  • MACD
  • XOMAP -0.06
  • NAMSW -0.12
  • Stochastic Oscillator
  • XOMAP 21.50
  • NAMSW 24.31

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: